References
- Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005;106:2605–12
- Regan F, Taylor C. Recent developments: blood transfusion medicine. BMJ 2002;325:143–7
- Ortel TL, Mercel MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001;233:88–96
- Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007;205:256–65
- Bishop PD, Lewis KB, Schultz J, Walker KM. Comparison of recombinant human thrombin and plasma-derived human α-thrombin. Semin Thromb Hemost 2006;32:86–97
- Evicel® Fibrin sealant. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm114073.pdf [last accessed 23 May 2014]
- Recothrom®. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm120557.pdf [last accessed 23 May 2014]
- Beriplast P Combi-Set. Available from: http://www.cslsurgery.com/international/beriplast/product/pdf/eu/Expert.pdf [last accessed 23 May 2014]
- Miller SC, Drabik BR. Rheological properties of poloxamer vehicles. Int J Pharm 1984;18:269–76
- Schmolka IR. Artificial skin I. Preparation and properties of pluronic F-127 gels for tratment of burns. J Biomed Mater Res 1972;6:571–82
- Shin BK, Baek EJ, Choi SG, et al. Preparation and irradiation of Pluronic F127 – based thermoreversible and mucoadhesive hydrogel for local delivery of naproxen. Drug Dev Ind Pharm 2013;39:1874–80
- Bromberg LE, Ron ES. Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. Adv Drug Dev Rev 1998;31:197–221
- Nasir F, Igbal Z, Khan A, et al. Development and evaluation of pluronic- and methylcellulose-based thermoreversible drug delivery system for insulin. Drug Dev Ind Pharm 2013. [Epub ahead of print]. (doi:10.3109/03639045.2013.831441)
- Rossi S, Ferrari F, Bonferoni MC, et al. Comparison of poloxamer- and chitosan-based thermally sensitive gels for the treatment of vaginal mucositis. Drug Dev Ind Pharm 2014;40:352–60
- Kianfar F, Ayensu I, Boateng JS. Development and physico-mechanical characterization of carrageenan and poloxamer-based lyophilized matrix as a potential buccal drug delivery system. Drug Dev Ind Pharm 2014;40:361–9
- Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res 2010;27:544–75
- Ugwu SO, Apte SP. The effect of buffers on protein conformational stability. Pharm Technol 2004;28:86–108
- Fenton JW, Fasco MJ, Stackrow AB. Human thrombins. Production, evaluation, and properties of α-thrombin. J Biol Chem 1977;252:3587–98
- Lanchantin GF, Friedman JA, Hart DW. Two forms of human thrombin. Isolation and characterization. J Biol Chem 1973;248:5956–66
- Le Borgne S, Graber M. Amidase activity and thermal stability of human thrombin. App Bioch Biotech 1994;48:125–35
- Jiang S, Senderoff R, Meyer JD. Thrombin compositions. Zymogentics Inc. US Patent 7,393,674 B2
- Juhasz J, Lenaerts V, Tan PVM, Ong H. Effect of sodium chloride on physical characteristics of poloxamer 407 solutions. J Coll Int Sci 1990;136:168–74
- Her LM, Deras M, Nail SL. Electrolyte-induced changes in glass transition temperatures of freeze-concentrated solutes. Pharm Res 1995;12:768–72
- Calvalho FC, Calixto G, Hatakeyama IN, et al. Rheological, mechanical, and bioadhesive behavior of hydrogels to optimize skin delivery systems. Drug Dev Ind Pharm 2013;39:1750–7
- Herler J, Engesland A, Kermany BP, Škalko-Basnet N. Improved texture analysis for hydrogel characterization: gel cohesiveness, adhesiveness and hardness. J App Polym Sci 2012;125:180–8
- Ozcan I, Abaci O, Uztan AH, et al. Enhanced topical delivery of terbinafine hydrochloride with chitosan hydrogels. AAPS Pharm Sci Tech 2009;10:1024–34
- Lewis L, Johnson RE, Oldroyd ME, et al. Characterizing the freeze-drying behavior of model protein formulations. AAPS Pharm Sci Tech 2010;11:1580–90
- Patapoff TW, Overcashler DE. The importance of freezing on lyophilization cycle development. BioPharm 2002;15:16–21
- Searles SA, Carpenter JF, Randolph TW. Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine T(g)' in pharmaceutical lyophilization. J Pharm Sci 2001;90:872–87
- Schersch K, Betz O, Garidel P, et al. Systemic investigation of the effect of lyophilized collapse on pharmaceutically relevant proteins I: stability after freeze-drying. J Pharm Sci 2010;99:2256–78
- Cao W, Krishnan S, Ricci MS, et al. Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies. Eur J Pharm Biopharm 2013;85:287–93
- Lewis L, Johnson RE, Oldroyd ME, et al. Characterizing the freeze-drying behavior of model protein formulations. AAPS PharmSciTech 2010;11:1580–90
- Blue J, Yoder H. Succesful lyophilization development of potein therapeutics. Am Pharm Rev 2009;12:90–6
- Shire SJ, Shahrokh Z, Liu J. Challanges in the development of high protein concetration formulations. J Pharm Sci 2004;93:1390–402
- Xolair®. Available from: http://www.xolair.com/hcp/how-to-prepare-and-administer-xolair.html [last accessed 27 May 2014]
- Haemosolvate®. Available from: http://home.intekom.com/pharm/nbi/viii1000.html [last accessed 27 May 2014]
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203:1–60